Daiwa Downgrades Abbott Laboratories, Cuts Price Target
Daiwa downgraded Abbott Laboratories (ABT) to Neutral from Outperform and reduced its price target to $92 from $113. The move comes amid mixed performance and cautious guidance from the company, which expects second-quarter adjusted EPS between $1.25 and $1.31. Barclays also adjusted its price target, though it maintained an Overweight rating.
Tickers: $ABT
Topics: Abbott Laboratories analyst report price target change stock downgrade